The crucial component of treatment protocols of CML and Ph+ B-ALL patients are tyrosine kinase inhibitors (TKIs), drugs which target both BCR-ABL1 isoforms. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.